Loading market dashboard
Sionna Therapeutics, Inc.
SIONHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
WALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in the following upcoming investor events:
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th, 2026, at 2:05 p.m. ET.
Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer of 2026 Maintained strong cash position with approximately $289.9 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Topline data is on track for anticipated readout in the summer of 2026 Topline data is on track for anticipated readout in the summer of 2026
Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Orbimed Advisors Llc sold 47,814 shares of the company's stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $44.51, for a total transaction of $2,128,201.14. Following the completion of the sale, the director directly owned 3,482,888 shares of
Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Peter Thompson sold 47,814 shares of the firm's stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $44.51, for a total transaction of $2,128,201.14. Following the completion of the transaction, the director owned 3,482,888 shares in
Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Orbimed Advisors Llc sold 226,906 shares of the business's stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $45.34, for a total transaction of $10,287,918.04. Following the transaction, the director directly owned 3,020,119 shares in the
Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Orbimed Advisors Llc sold 235,863 shares of the firm's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares of the company's stock,
Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Peter Thompson sold 226,906 shares of the company's stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $45.34, for a total transaction of $10,287,918.04. Following the completion of the sale, the director directly owned 3,020,119 shares in the
Sionna Therapeutics, Inc. (NASDAQ: SION - Get Free Report) Director Peter Thompson sold 235,863 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares of the company's stock, valued at
WALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14th, 2026.
Jennifer Fitzpatrick sold 10,250 shares for a total of approximately $347,000 on March 5, 2026. This transaction represented 100.00% of her direct common stock holdings, reducing direct ownership of common stock to zero.
Superstring Capital Management acquired 180,593 shares of Sionna Therapeutics in the fourth quarter. The quarter-end position value rose by $7.43 million, reflecting the purchase of a new position.
OrbiMed Advisors sold 143,304 shares of Sionna Therapeutics in the fourth quarter; the estimated transaction value was $5.43 million based on quarterly average prices. Meanwhile, the quarter-end position value increased by $37.56 million, reflecting both trading and stock price movement.
